Robert Gardner Harrison Sells 14,209 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Robert Gardner Harrison sold 14,209 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now owns 116,837 shares in the company, valued at approximately $863,425.43. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Gardner Harrison also recently made the following trade(s):

• On Monday, January 13th, Robert Gardner Harrison sold 2,264 shares of Sera Prognostics stock. The shares were sold at an average price of $6.47, for a total value of $14,648.08.

Sera Prognostics Trading Up 3.8 %

Shares of Sera Prognostics stock opened at $6.61 on Thursday. The company’s 50-day moving average price is $7.44 and its 200-day moving average price is $7.31. The company has a market cap of $223.23 million, a price-to-earnings ratio of -6.68 and a beta of 0.86. Sera Prognostics, Inc. has a 12-month low of $4.98 and a 12-month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the firm posted ($0.23) earnings per share. On average, sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Hedge Funds Weigh In On Sera Prognostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after acquiring an additional 75,441 shares in the last quarter. Rhumbline Advisers purchased a new stake in Sera Prognostics in the second quarter valued at approximately $190,000. American Century Companies Inc. lifted its position in Sera Prognostics by 12.7% during the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after purchasing an additional 2,891 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Sera Prognostics in the 2nd quarter worth approximately $162,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Sera Prognostics in the 2nd quarter worth $68,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.